(Q47613939)

English

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

title

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

author name string

Aledort LM

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

publication date

1 June 2004

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

published in

Journal of Thrombosis and Haemostasis

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

volume

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

page(s)

861-862

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

cites work

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00731.X

retrieved

21 January 2018

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00731.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1538-7836.2004.00731.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

PubMed publication ID

15140115

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15140115

retrieved

4 February 2018

reference URL

http://europepmc.org/abstract/MED/15140115

ResearchGate publication ID

8566087

0 references

(Q47613939)

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)